✦ LIBER ✦

Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients

✍ Scribed by Rey-Yue Yuan; Jau-Jiuan Sheu; Jia-Ming Yu; Chaur-Jong Hu; Ing-Jy Tseng; Chun-Sum Ho; Ching-Ying Yeh; Ya-Lin Hung; Tsuey-Ru Chiang

Book ID: 119303561
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 182 KB
Volume: 287
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2009.09.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hyperhomocysteinemia and methylenetetrah

Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease

✍ D. Religa; K. Czyzewski; M. Styczynska; B. Peplonska; J. Lokk; M. Chodakowska-Ze 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Tolcapone decreases plasma levels of S-a

Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patients

✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 97 KB

Hyperhomocysteinemia recurrence in levod

Hyperhomocysteinemia recurrence in levodopa-treated Parkinson’s disease patients

✍ V. Belcastro; L. Pierguidi; A. Castrioto; C. Menichetti; G. Gorgone; R. Ientile; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Cysteine elevation in levodopa-treated p

Cysteine elevation in levodopa-treated patients with Parkinson's disease

✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cystei

Hyperhomocysteinemia in levodopa-treated

Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia

✍ Stefano Zoccolella; Claudia dell'Aquila; Giovanni Abruzzese; Angelo Antonini; Ub 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was

Effects of levodopa and COMT inhibitors

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T